Aria Pharmaceuticals ( ARIA -6% ) increases its debt offering to qualified institutional investors to $200M aggregate principal amount. The 3.625% convertible senior notes due 2019 will be sold via private placement. Underwriters over
ARIAD Pharmaceuticals ( ARIA +1.9% ) plans to offer $175M aggregate principal amount convertible senior notes due 2019 in a private placement to qualified
ARIAD Pharmaceuticals , Inc. ( ARIA ) Jefferies 2014 Global Healthcare ..... next presenting company is ARIAD Pharmaceuticals . ARIAD is a cancer -- largely ..... is the one representing from ARIAD Pharmaceuticals . And Tim is the President
Ariad Pharmaceuticals Inc. ( ARIA ) ARIAD Investor and Analyst Briefing from ASCO Conference Transcript June 2, 2014 8:30 AM ET Executives Dr. Lyud Bazhenova
In a 34-patient Phase 2 trial , Ariad Pharmaceuticals ' ( ARIA ) Iclusig (ponatinib) shows a clinical benefit in 50% of patients with refractory metastatic and/or unresectable gastrointestinal
Nov 1 (Reuters) - Ariad Pharmaceuticals Inc adopted a shareholder rights plan to protect its tax credits, a day after sales of its flagship drug Iclusig were suspended due to safety concerns...